FDA approves cancer drug using novel endpoint

The US Food and Drug Administration has used a novel endpoint to approve a new drug for prostate cancer. Measuring metastasis-free survival, the agency decided that the Janssen Pharmaceutical drug Erleada (apalutamide) is effective.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States